Simultaneous Determination of Ticlopidine Hydrochloride and Nitrendipine in a New Tablet Formulation by HPLC

An accurate, simple and sensitive high performance liquid chromarographic (HPLC) method for simultaneous determination of ticlopidine hydrochloride and nitrendipine in a new tablet formulation is described. Chromatographic separation of ticlopidine hydrochloride and nitrendipine was achieved on a Hypersil BDS C18 column using a mobile phase consisting of acetonitrile-methanol-10 mmol/L ammonium acetate (60∶10∶30(V/V), pH 6.5) at a flow rate of 1.0 mL/min. Absorbance was monitored at 236 nm where both drugs have significant absorption. The proposed method was validated with respect to linearity, selectivity, accuracy, precision, and limits of detection and quantitation. The linear ranges for ticlopidine hydrochloride and nitrendipine were found to be 75-750 μg/mL and 1-10 μg/mL, respectively. The mean recoveries were 100.1%(S R=0.6%,n=9) for ticlopidine hydrochloride and 99.9%(S R=0.7%,n=9) for nitrendipine. The within-day precision and between-day precision for ticlopidine hydrochloride and nitrendipine were 0.63% and 0.89%, and 0.74% and 1.0%, respectively. The proposed HPLC method can be used for the simultaneous determination of both drugs in pharmaceutical preparations.

抗血小板药Ticlopidine的合成

用2-(2-噻吩)乙醇为原料合成了Ticlopjdine。制备中间体(2)时,以吡啶代替三乙胺及异丙醚,反应时间由70h减少到8h;制备中间体(3)时,以甲苯为溶剂回流优于用乙腈,最后成盐一步,将Ticlopidine盐基用浓盐酸及丙酮处理,产品质量令人满意。

Ticlopidine抑制血小板聚集的临床抗栓研究

研究证明Ｔｉｃｌｏｐｉｄｉｎｅ有明显的血小板聚集抑制作用，延长出血时间，对ＴＸＡ２和ＰＧＩ２无影响，临床有抗栓疗效，无明显毒副作用。

Effect of pretreatment with aspirin and ticlopidine on the change of platelet aggregability after radiofrequency catheter ablation

Eighty-two patients with supraventricular tachycardia undergoing radiofrequency catheter ablation (RFCA) were studied to observe the inhibition effect of aspirin and ticlopidine on platelet aggregability (PAG) and thromboxane B 2(TXB 2) of the blood samples. Patients were divided into aspirin group A, ticlopidine group B, aspirin+ticlopidine group C and control group D. PAG and TXB 2 were increased clearly after RFCA in all groups (P<0.001). Treatment with aspirin or ticlopidine before operation could reduce the platelet aggregability caused by RFCA and the joint effect of two drugs(change rate of group A:52.51±12.51%; group B:54.78±11.27%;group C: 30.51±10.59%;group D:91.75±21.43%; P<0.05)was studied. The much decreased platelet aggregability after antiplatelet therapy was evidence of the potential benefit of the treatment in preventing thromboembolism after ablation. Pretreatment with aspirin and ticlopidine together is a good way to decrease palatelet aggregability after RFCA.

Aspirin,Ticlopidine,Clopidogrel三药临床应用比较

Aspirin,Ticlopidine(Ticlid),Clopidogrel(Plavix)三药都是抗血小板凝集的药物,临床常应用于血栓形成的预防及治疗。 Aspirin应用于临床已有百年历史,被誉为廿世纪的奇迹药物(wonder drug of the 20 th centruy)。自从1971年被证实它有抗血小板凝集作用后,在脑血管意外疾病,心血管疾病,以及某些外周血管疾病治疗中,Aspirin一直作为传统药物用来预防血栓形成。它是非处方药物,价格便宜。 自从药物Ticlopidine和Clopidogrel出现后,

抵克力得与川芎嗪联合治疗缺血性脑血管病的临床对比观察

目的用中西医结合的方法观察抵克力得 (Ticlopidine)与川芎嗪联合治疗缺血性脑血管病的临床疗效。方法将 5 2例病人 ,男 2 8例 ,女 2 4例分为两组 ,治疗组 32例 ,对照组 2 0例 ,治疗组Ticlopidine 2 5 0mgqd ,川芎嗪 80～ 140mg divgttqd ,1个月为 1个疗程。对照组单用Ticlopidine 2 5 0mgqd。结果治疗组总有效率优于对照组 (P <0 0 5 ) ,1年后复发率治疗组 12 5 % ,对照组 30 % ,低于国内大宗病例与阿斯匹林的比较。结论中西医结合治疗缺血性脑血管病优于单用Ticolpidine的治疗 ,两者联合应用 ,既预防又治疗 ,两者兼顾。